Drug Profile
Selexipag - Actelion/Nippon Shinyaku
Alternative Names: ACT-293987; JNJ-678896049; NS-304; UptraviLatest Information Update: 15 Mar 2024
Price :
$50
*
At a glance
- Originator Nippon Shinyaku
- Developer Actelion Pharmaceuticals; Nippon Shinyaku
- Class Acetamides; Amines; Anti-inflammatories; Antithrombotics; Pyrazines; Small molecules; Sulfonamides; Vascular disorder therapies; Vasodilators
- Mechanism of Action Epoprostenol receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Pulmonary arterial hypertension; Pulmonary hypertension
- Phase III Arteriosclerosis obliterans
- Clinical Phase Unknown Thromboangiitis obliterans
- No development reported Raynaud's disease
- Discontinued Spinal stenosis
Most Recent Events
- 29 Feb 2024 Actelion terminates a phase II/III trial for Pulmonary arterial hypertension in USA, UK, Netherlands, Hungary, Germany, Poland, Spain, Brazil, Belgium, Canada, France and Italy due to the lower-than-expected recruitment rate (NCT03942211) (EudraCT2018-004887-74)
- 19 May 2023 Pooled efficacy data from the phase III GRIPHON, SERAPHIN and COMPASS-2 trials in Pulmonary arterial hypertension presented at the 119th International Conference of the American Thoracic Society (ATS-2023)
- 28 Feb 2023 No recent reports of development identified for phase-I development in Pulmonary-arterial-hypertension(In volunteers) in Belgium (PO, Controlled release)